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Mice infected with coxsackievirus B1 Tucson (CVB1T) develop chronic, post-viral myopathy (PVM) with clinical manifestations of hind limb
muscle weakness and myositis. The objective of the current study was to establish the genetic basis of myopathogenicity in CVB1T. Using a
reverse genetics approach, full attenuation of PVM could only be achieved by simultaneously mutating four sites located at C706U in the 5′
untranslated region (5′ UTR) and at Y87F, V136A, and T276A in the VP1 capsid. Engineering these four myopathic determinants into an
amyopathic CVB1T variant restored the ability to cause PVM. Moreover, these same four determinants controlled PVM expression in a second
strain of mice, indicating that the underlying mechanism is operational in mice of different genetic backgrounds. Modeling studies predict that
C706U alters both local and long range pairing in the 5′ UTR, and that VP1 determinants are located on the capsid surface. However, these
differences did not affect viral titers, temperature stability, pH stability, or the antibody response to virus. These studies demonstrate that PVM
develops from a complex interplay between viral determinants in the 5′ UTR and VP1 capsid and have uncovered intriguing similarities between
genetic determinants that cause PVM and those involved in pathogenesis of other enteroviruses.
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The type B coxsackieviruses (CVB, serotypes 1–6) are
members of the enterovirus genus in the family Picornaviridae.
CVB are nonenveloped viruses comprised of an icosahedral
capsid enclosing a single-stranded, positive-sense RNA genome
of approximately 7.4 kb (Muckelbauer et al., 1995). Infection
begins with virus binding to the coxsackievirus and adenovirus
receptor (CAR), the primary cellular receptor for CVB (Ber-
gelson et al., 1997; Carson et al., 1997; Tomko et al., 1997).
CAR facilitates CVB internalization and uncoating through
interactions with the canyon surrounding the 5-fold axis of
symmetry on the viral capsid (He et al., 2001). A variety of⁎ Corresponding author. Fax: +1 612 625 7170.
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doi:10.1016/j.virol.2007.10.020alternate or co-receptors has also been described including decay
accelerating factor (DAF; CD55) (Bergelson et al., 1995) and
heparan sulfate (Zautner et al., 2003). Following cell entry, viral
RNA is translated through a cap-independent mechanism in-
volving the viral internal ribosome entry site (IRES) and host
proteins (reviewed by Belsham and Sonenberg (2000)). The
resulting polyprotein is processed through a series of cleavages
by viral proteases 2A and 3CD into four capsid proteins encoded
by genomic region P1 and seven nonstructural proteins in re-
gions P2 and P3. Replication ensues via production of negative-
strand RNA that serves as a template for the synthesis of large
amounts of positive strands to be translated or encapsidated into
new virions. The 5′ UTR plays an important role in controlling
the processes of viral replication and translation (reviewed by
Bedard and Semler (2004)).
CVB infections are one of the most frequent causes of myo-
carditis and its sequela, dilated cardiomyopathy, and may also be
a factor in the development of type I diabetes (reviewed by
Fig. 1. Histopathology of myositis in PVM at 1 month PI. Grade 2 myositis
caused by MP1.24 infection is indicated by the presence of medium-sized
mononuclear cell infiltrates (⁎). Other signs of pathology compared to un-
infected muscle (shown in inset, lower right) include fatty replacement, inter-
stitial fibrosis, changes in fiber diameter and shape, and the presence of central
nuclei (original magnification ×200).
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tropism, CVB and related enteroviruses have also been impli-
cated in pathogenesis of chronic muscle diseases such as chronic
fatigue syndrome, fibromyalgia, and myositis (Chia and Chia, in
press; Clements et al., 1995; Douche-Aourik et al., 2003) and
reviewed by Chia (2005)). Although they are primarily cyto-
pathic, enteroviruses persist in some chronic fatigue syndrome
patients (Chia and Chia, in press; Galbraith et al., 1997) in a form
where the ratio of positive and negative viral RNAs is appro-
ximately equal (Cunningham et al., 1990). Despite these
and other supportive studies, a number of investigations have
failed to link these viruses to chronic myositis or fatigue syn-
dromes (Leon-Monzon and Dalakas, 1992; Lindh et al., 1996;
McArdle et al., 1996), raising questions regarding differences
in the timing, geographic location, and myopathic potential of
enterovirus infections.
The possibility that CVB infection is a factor in the patho-
genesis of chronic myopathies is demonstrated by an experi-
mental model where acute cytopathic infection of newborn
mice with CVB1T causes long-term sequelae including inflam-
mation of proximal hind limb skeletal muscle and changes in
gait, referred to as weakness (Ray et al., 1979; Strongwater et al.,
1984). Expression of clinical weakness is asymmetric, associ-
ated with increased muscle necrosis, and does not vary once
established (Jongen et al., 1996; Tam et al., 1994). By com-
parison, myositis peaks around 1 month post-infection (PI) and
gradually dissipates by 6 months (Tam et al., 1994). The affected
muscle displays a characteristic histopathology that includes
focal mononuclear inflammatory cell infiltrates, permanent
loss of muscle mass with fatty replacement, myofiber hypertro-
phy, endomysial and perimysial fibrosis, and increased num-
bers of mast cells (Tam et al., 1994). Infectious virus is cleared
by 2 weeks PI but viral RNA persists in the hind limb muscle
of some mice for as long as 12 months (Tam et al., 1994). At
1 month PI, viral RNA can be seen in areas coincident with
inflammation and tissue damage as well as in histologically
normal areas as a “silent” infection (Tam et al., 1991, 1994).
Similar to patient studies, roughly equivalent amounts of po-
sitive and negative strands persist in a double-stranded con-
formation, indicating that viral replication is altered (Tam and
Messner, 1999).
Successive passage of CVB1T through BGMK cells pro-
duces variants that cause a robust acute infection but are
attenuated for PVM, indicating that PVM is controlled by
distinct viral determinants (Tam and Messner, 1997). Sequence
comparisons suggest that five mutations–C706U in the 5′ UTR,
Y87F, V136A, and T276A in capsid protein VP1, and K53E in
the viral 3C protease–are prime candidates for PVM attenuation
(Tam et al., 2003b). Additional genetic differences include six
translationally silent mutations that segregate with myopatho-
genicity. In the current study, we conclusively identified the
viral determinants responsible for PVM and delineated their
relationship to pathogenesis of chronic weakness and inflam-
mation. Predicted structural changes caused by mutations in the
5′ UTR and VP1 capsid have provided further insight into how
enteroviruses evolve to produce a diverse spectrum of diseases
(reviewed by Tracy et al. (2006)).Results
Myopathogenicity of CVB1T is encoded by viral genetic
determinants in the 5′ UTR and VP1
Previous studies of viral chimeras constructed from cloned
viruses MP1.24 and AMP2.17 indicated that more than one
region of the viral genome contributes to the development of
chronic hind limb weakness and inflammation following
infection (Tam et al., 2003b). In addition, comparative se-
quencing of MP1.24, AMP2.17, additional virus clones, and the
parental strains from which they were derived identified eleven
mutations that segregate with the myopathic or amyopathic
phenotype of the virus including one in the 5′ UTR, four that
cause coding changes, and six that are translationally silent. The
initial objective of the current study was to determine if the
ability ofMP1.24 to cause PVMwas strictly encoded within five
determinants located at C706U in the 5′ UTR, Y87F, V136A,
and T276A in the VP1 capsid protein, and K53E in the 3C
protease. An attenuation strategy was employed in which the
MP1.24 infectious myopathic clone was mutated to the amyo-
pathic nt at one or more of the five putative determinants.
Myopathogenicity was based on the severity of clinical hind
limb weakness and histological grading of myositis in the
hamstring muscle at 1 month after infection (Fig. 1), which is on
average two weeks after infectious virus can be recovered.
AMP2.17-infected mice resembled the uninfected control ex-
cept for a few cases with grade 1 weakness or grade 1 inflam-
mation, consistent with previous comparisons of myopathic
and attenuated strains (Tam and Messner, 1997; Tam et al.,
2003b). ANOVA followed by post-hoc comparisons of each
mutagenized construct with the myopathic MP1.24 and amyo-
pathic AMP2.17 prototype viruses was used to characterize
the pathogenic phenotype of each mutant as either myopathic,
Fig. 2. PVM phenotype in CD-1 mice infected with different mutated constructs of CVB1T at 1 month PI. (A) Statistical analysis by ANOVA with pairwise
Bonferroni–Dunn post-hoc comparisons was used to compare chronic hind limb weakness and muscle inflammation grades for mutated viral constructs with the
MP1.24 and AMP2.17 controls. This analysis was the basis for categorizing each construct as either myopathic (different from AMP2.17 but not MP1.24),
amyopathic (different from MP1.24 but not AMP2.17), or intermediate (different from both MP1.24 and AMP2.17). The dotted lines demarcate these statistically
significant differences, shown as sectors I–IX. For example, sector III contains fully myopathic viruses, sector I contains viruses that were myopathic for
inflammation but amyopathic for weakness, and sector VII contains constructs that were fully attenuated. (B) Expression of weakness and inflammation in
individual mice infected with MP1.24. The number of mice at each combination of grades, which extends from 0 to 3 for myositis and 0 to 6 for weakness, is
shown.
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scheme is described in further detail in the Fig. 2 legend.
Mutation of MP1.24 at all five positions in virus construct A-
AAA-A (see Table 1 legend for description of viral genotype
scheme) attenuated weakness and inflammation to a degree that
was comparable to AMP2.17 (Table 1A and Fig. 2A), indicating
that myopathogenicity was encoded within these five candidate
determinants. Furthermore, mutation of the three VP1 determi-
nants inM-AAA-M fully attenuated its ability to cause weakness.
These capsid mutations also reduced but did not fully attenuate
myositis, placing M-AAA-M in sector IV and indicating that at
least one additional determinant was involved in pathogenesis of
PVM. Both A-MMM-M and M-MMM-Awere fully myopathic,
and the identity of the additional determinant was resolved by
engineering C706U into the M-AAA-M construct. The resulting
A-AAA-M virus (sector VII) was further attenuated for in-
flammation compared to M-AAA-M (P=0.003) and comparable
toA-AAA-A (PN0.05), suggesting that C706was involved in the
development of myositis even though no effect was observed for
the singly-mutated A-MMM-M construct (sector III). The
realization that there might be cooperative effects prompted us
to examine one additional construct, M-MMA-A, because pre-
vious chimeras indicated the presence of amyopathic determinant
downstream of nt 3200 (P250 inVP1) (Tam et al., 2003b) and yet,
in the current study, M-MMM-A was not attenuated. Partial
attenuation of M-MMA-A (sector V) was similar to what was
previously observed for the viral chimera and suggested that
T276A at nt 3278, either alone or in conjunction with K53E at nt
5510, was responsible.Individual viral determinants and their effect on chronic
weakness and inflammation
Additional studies were performed to clarify the role of VP1
capsid determinants by mutating each one individually to the
amyopathic form (Table 1B and Fig. 2A). Because complete
attenuation of inflammation was observed only when C706Uwas
combinedwith three VP1mutations in construct A-AAA-M, each
VP1 determinant was mutated singly and in combination with
C706U to identify interacting determinants. Little to no weakness
was observed in mice infected with MP1.24 containing Y87F or
V136A in the M-AMM-M or M-MAM-M constructs, respec-
tively. By comparison, mutation at T276A in the M-MMA-M
construct only partially attenuated weakness development,
and C706U had no effect on weakness when combined with
any of the three capsid mutations. The pattern of involvement
for individual determinants of weakness partially overlapped
those responsible for myositis. As predicted by the M-AAA-M
construct, full attenuation of chronic myositis could not be
achieved by attenuating any one of the three capsid determi-
nants individually. M-AMM-M and M-MMA-M showed par-
tial attenuation of myositis while V136A in M-MAM-M had
no effect. A further reduction in myositis development oc-
curred by pairing individual capsid mutation Y87Fwith C706U
in A-AMM-M but not in A-MAM-M or A-MMA-M. C706U
reduced the mean inflammation grade from 0.7 for M-AMM-M
to 0.5 for A-AMM-M. This was sufficient to shift A-AMM-M
into the statistically-determined amyopathic category, even
though the inflammation grades did not differ significantly
Table 2
Mortality, viral replication, and host antibody response to CVB1T mutants
Survival
(%) a
Virus titer b Anti-viral antibody
(Log TCID50/gm
muscle)
(Log U/ml)
Controls
MP1.24 84 7.4±0.3 3.8±0.03
AMP2.17 89 7.5±0.4 3.6±0.03
PBS 91 NDc ND
Mutant virus genotype
(A)
A-AAA-A 100 6.7 ±0.5 3.6±0.06
M-AAA-M 84 7.5±0.5 3.5±0.07
A-MMM-M 79 7.6±0.3 3.7±0.03
M-MMM-A 96 7.6±0.2 3.6+ 0.03
A-AAA-M 83 7.1±0.5 3.6±0.07
M-MMA-A 97 8.1±0.4 3.7±0.05
(B)
M-AMM-M 100 7.5±0.2 3.7±0.04
A-AMM-M 100 6.9±0.5 3.6±0.02
M-MAM-M 100 7.1±0.5 3.8±0.03
A-MAM-M 100 6.9±0.4 3.7±0.02
M-MMA-M 97 6.5±0.4 3.6±0.04
A-MMA-M 92 6.4±0.3 3.8±0.04
(C)
(M-MMM)-A 87 6.8±0.4 3.7±0.04
a Survival is the percentage of mice that survived acute infection during the
first two weeks PI. Log rank comparisons with the PBS control were not
significant (PN0.05).
b Values for virus titer (at 6 days PI) and anti-viral antibody (at 1 month PI) are
presented as the mean±1 SEM. ANOVA performed on virus titers or anti-viral
antibodies was not significant (PN0.05).
c ND, none detected.
Table 1
Chronic hind limb weakness and proximal skeletal muscle inflammation in mice
infected with CVB1T mutants
Virus Weakness Inflammation
Grade a
(mean±SEM)
% (no.
positive/
total)
Grade
(mean±SEM)
% (no.
positive/
total
Controls
MP1.24 2.1±0.2 72 (69/96) 1.7±0.1 88 (57/65)
AMP2.17 0.2±0.04⁎ 16 (13/79)⁎ 0.1±0.03⁎ 5 (4/74)⁎
PBS 0⁎ 0 (0/76)⁎ 0⁎ 0 (0/38)⁎
Mutant
virus genotype b
(A)
A-AAA-A 0.1±0.1⁎ 10 (2/19)⁎ 0.1±0.1⁎ 10 (2/19)⁎
M-AAA-M 0⁎ 0 (0/25)⁎ 0.8±0.2⁎ 44 (11/25)⁎
A-MMM-M 1.7±0.2 72 (34/47) 1.8±0.2 85 (33/39)
M-MMM-A 1.8±0.3 72 (29/40) 1.7±0.2 89 (17/19)
A-AAA-M 0⁎ 0 (0/27)⁎ 0.1±0.06⁎ 12 (3/26)⁎
M-MMA-A 1.0±0.3⁎ 41 (11/27)⁎ 0.7±0.2⁎ 41 (11/27)⁎
(B)
M-AMM-M 0⁎ 0 (0/28)⁎ 0.7±0.2⁎ 52 (13/25)⁎
A-AMM-M 0.3±0.1⁎ 21 (6/29)⁎ 0.5±0.2⁎ 38 (8/21)⁎
M-MAM-M 0.2±0.1⁎ 13 (4/30)⁎ 1.4±0.2 77 (20/26)
A-MAM-M 0.3±0.1⁎ 25 (7/28)⁎ 1.2±0.2 83 (19/23)
M-MMA-M 0.9±0.2⁎ 50 (14/28) 0.7±0.2⁎ 50 (14/28)⁎
A-MMA-M 1.0±0.2⁎ 58 (18/31) 0.6±0.2⁎ 35 (11/31)⁎
(C)
(M-MMM)-A 1.5±0.3 68 (17/25) 1.3±0.2 79 (19/24)
a Viruses causing weakness or inflammation that differed from MP1.24 at
1 month PI are indicated (*). ANOVA with Bonferroni–Dunn post-hoc testing
was used to compare grades and Fisher's exact test was used to compare
incidence (adjusted for fifteen comparisons, level of significance α=0.003).
b The viral “genotype” at each of five positions is represented by an “M” for
myopathic and an “A” for amyopathic. The genotype is shown in the order 5′UTR-
VP1-3C or C706U-Y87FV136AT276A-K53E, where the preceding nucleotide or
residue is found in MP1.24 and the following one is in AMP2.17. Viral constructs
shown in (A) and (B) were generated by site-directed mutagenesis of the MP1.24
clone to the amyopathic determinant. The revertant in (C) was produced by
mutagenesis of AMP2.17 to myopathic determinants (enclosed by parentheses) in
the 5′ UTR and VP1.
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(PN0.05) (Fig. 2A sectors IV and VII). These data rein-
forced a role for C706U in myositis and suggested that Y87F
was the interacting determinant responsible for enhanced at-
tenuation of the A-AAA-M construct. Noting the trend in
Fig. 2A, it is also possible that the full effect of C706U is
manifest in combination with all three capsid mutations as
observed for A-AAA-M in sector VII. Additional comparisons
of M-MMA-M with M-MMA-A reinforced the previous as-
sumption that K53E was non-attenuating since these con-
structs caused similar degrees of weakness and inflammation
(PN0.05), resulting in an intermediate phenotype for both.
In the final analysis four determinants, C706, Y87, V136, and
T276, were implicated in pathogenesis of PVM. To confirm their
involvement, AMP2.17 was engineered to contain mutations
U706C, F87Y, A136V, and A276T. Construct (M-MMM)-A
reverted to a myopathic phenotype, further establishing the
importance of these determinants (Table 1C and Fig. 2A sector
III). The inflammation and weakness scores for (M-MMM)-A
were slightly lower than other myopathic constructs, whichcould be due to experimental variation or may indicate that some
additional determinant is lacking in the AMP2.17 genome. The
incidence of affected mice mirrored what was observed by
grading the severity of weakness or inflammation (Table 1). One
exception was the incidence of weakness in constructs contain-
ing T276A either alone or paired with C706U or K53E. The
percentage of weak mice in these three groups ranged from 41%
to 58%, which was less than the 72% observed for the MP1.24
control but only significant for construct M-MMA-A. T276 was
not a strong determinant of weakness which may explain its
marginal effect on incidence. For inflammation, the incidence
was completely concordant with the mean severity scores for
each group. Notably, the incidence for A-AAA-M was 12%
compared to 44% for M-AAA-M, further supporting the
involvement of C706 in pathogenesis. Overall, the mapping
studies indicated that Y87F was highly attenuating for weakness
and moderately attenuating for inflammation unless combined
with C706U. V136A was unique in that it caused strong atten-
uation of weakness but had no effect on inflammation, while
T276A emerged as a moderate attenuator of both.
Viral determinants distinguish between pathogenesis of
weakness and inflammation
Teasing out the differential involvement of individual viral
determinants showed that two, V136 and C706, had distinct
39M.M. Sandager et al. / Virology 372 (2008) 35–47effects on the pathogenesis of weakness and inflammation,
respectively. This relationship is apparent in Fig. 2A, where
V136A (M-MAM-M) stands alone in sector I for weakness
attenuation. In contrast, the absence of viral constructs in sectors
VIII and IX indicates that there is no combination of mutations
that promotes weakness in the absence of inflammation. The
distribution of disease phenotypes is recapitulated in mice
infected with MP1.24 where 15 of 65 mice developed some
degree of myositis in the absence of weakness, and only 4 mice
showed low grade weakness in the absence of inflammation
(Fig. 2B). The remaining three myopathic viruses in sector III
showed a similar distribution (data not shown).
Attenuating determinants do not alter acute virulence, viral
stability, or the host antibody response to virus
Acute virulence was evaluated as the percentage of mice that
survived infection and the ability of virus to replicate in proximal
muscle at 6 days PI (Table 2). None of the mutations causedFig. 3. Viral stability and specificity of the antibody response to infection. Thermal sta
stability was determined at a pH of 4.5 (B). Serum from mice at 1 month PI that wer
virus in an ELISA (C) or in a viral neutralization assay (D). Regression analysis indica
Control serum from uninfected mice was negative in both the ELISA and neutralizasignificant differences in animal mortality or the ability of virus to
replicate in muscle, similar to what has previously been observed
for the prototypes MP1.24 and AMP2.17 or the original parental
strains of viruses used to generate these clones, which were tested
atmultiple time points over the 14-day infectious period (Tam and
Messner, 1997; Tam et al., 2003b). IgG antibody titers were also
comparable, and thus the ability to react withMP1.24 as a target in
the ELISA did not appear to be affected by the VP1 mutations.
Potential changes in the physical stability of the capsid were
evaluated at three different temperatures and at lowered pH (Figs.
3A and B). Decay of infectivity proceeded more rapidly at higher
temperatures but was comparable for MP1.24 and AMP2.17.
Moreover, the A-AAA-M construct behaved similarly when
tested at 39 °C. The characteristic stability of enteroviruses at
pH 4.5 was also unaltered (Fig. 3B). To further examine pos-
sible effects of the capsid mutations on antibody recognition,
serum from a randomly-selected subset of mice infected with
either MP1.24 or AMP2.17 was evaluated for cross-reactivity.
Serum antibodies from individual mice reacted equally wellbility of infectious virus was determined at 37 °C, 39 °C (A), and 47 °C (B). Acid
e infected with either MP1.24 or AMP2.17 was evaluated for reactivity to either
ted no difference between the slopes of the fitted lines in panels C or D (PN0.05).
tion assay (data not shown).
Fig. 4. PVM phenotype of selected viral constructs in BALB/c mice at 1 month PI. (A) BALB/c mice were infected with the indicated dose (TCID50) of virus and
evaluated for PVM at 1 month PI (N≥9). The mean grades for weakness (hatched bars) and inflammation (solid bars) are shown (ND, none detected). At an infectious
dose of 40 TCID50, weakness and inflammation scores for (M-MMM)-Awere significantly different from AMP2.17 and scores for A-AAA-A differed from MP1.24
(Pb0.0001). (B) Expression of weakness and inflammation in individual BALB/c mice infected with 20 or 40 TCID50 of MP1.24. The number of mice at each
combination of grades is shown.
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functional virus neutralization assay (Fig. 3D), regardless of
which virus was used for infection. Taken as a whole, these
experiments show that the attenuating mutations do not interfere
with virulence during the acute infection, do not cause capsid
instability, and do not affect the specificity of antibodies involved
in viral clearance.
Myopathic determinants control pathogenesis of PVM in
BALB/c mice
Several inbred mouse strains are susceptible to CVB1T-
induced PVM including A.BY/Sn, BALB/c, and DBA/2 (Tam
and Messner, 1996). CD-1 mice were used in the current expe-
riments because they were employed in earlier studies that impli-
cated multiple determinants (Tam et al., 2003a), and switching
to an inbred strain would run the risk of not being able to iden-
tify all the viral determinants. However, the question remained as
to whether myopathic determinants that control PVM in CD-1
mice also dictate disease expression in other susceptible strains.
BALB/c mice infected with 10, 20, or 40 TCID50 of MP1.24
showed a dose-dependent expression of PVMwhereas no signs of
PVM were apparent following infection with either 20 or 40
TCID50 of AMP2.17, indicating that the same determinants
might be involved (Fig. 4A). The lack of PVM in mice infected
withA-AAA-M and full expression of PVM inmice infectedwith
(M-MMM)-A suggests that the same four determinants, or at theFig. 5. Predicted effects of the C706U determinant on RNA secondary structure of the
mol) and (B) MP1.24 containing C706U (dG=−243.5 kcal/mol) are shown in a circul
nt intervals. Domain structures I–VII and the predicted SLK region are indicated. Re
circle periphery.very least a subset, also control disease in BALB/c mice. As
observed for CD-1 mice, virus constructs caused similar acute
infections measured by virus titers in muscle and the presence of
circulating antibody (data not shown). Infection with MP1.24
caused a phenotype distribution similar to that in Fig. 2B, with
most mice affected by both weakness and inflammation but
some displaying inflammation in the absence of weakness
(Fig. 4B). Chi-square analysis indicated that this distribution
did not differ between CD-1 and BALB/c mice (P=0.2). Thus,
determinants mapped in outbred CD-1 mice were equally
pathogenic in BALB/c mice, indicating that the mechanism is
closely tied to the genetics of the virus and is not restricted by
differences in the genetic background of these two host strains.
Attenuating mutations cause predicted changes in RNA
structure and the capsid surface
Computer modeling of the CVB1T 5′ UTR predicted that
C706U exerts local as well as long range effects on RNA se-
condary structure (Fig. 5). The models are presented as circular
Feynman diagrams to facilitate the comparison of long range
structural changes. Alignment with the current domain model of
the CVB3 5′ UTR, which extends from nt 1–647 (Bailey and
Tapprich, 2007) but does not include the downstream spacer
region, indicated that domains I, II, and VI were unaffected by
C706U. The most noticeable effect was observed locally with
disruption of a predicted stem loop that is smaller but analogous5′ UTR. Secondary structures of the 5′ UTR for (A) MP1.24 (dG=−244.7 kcal/
ar Feynman representation with paired nt connected by arcs and numbering at 50
gions where pairing is altered by C706U are indicated by black bars around the
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Fig. 6. Homology modeling of VP1 capsid determinants. A model of the capsid protomer containing VP1 (white), VP2 (light blue), VP3 (dark blue), and VP4 (yellow)
was generated from the atomic structure of CVB3 using the program Modeller. The three VP1 determinants are indicated in red for (A) MP1.24 and (B) MP1.24
containing Y87F, V136A, and T276A.
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extends from nt 670–708 in MP1.24. C706U resulted in a
smaller stem and hairpin loop at nt 680–693 followed by a
large unpaired region spanning nt 702–732. C706U also af-
fected long range interactions, causing new pairings between nt
641–701 and nt 229–247 in domains III and IV as well as
changes that did not directly involve SLK. These included
altered pairing between the 5′ basal region of domain IV (nt
250–260) with the basal stem of domain V (nt 453–462) and a
new stem loop formed by internal pairing of nt 424–451, both
of which involve sequences in the 5′ end of the IRES, as well as
a larger stem loop upstream within domain III.
Alignment and homology modeling of the CVB1T capsid
sequences with the three dimensional coordinates of CVB3
indicated that all three VP1 determinants are likely to be ex-
posed on the capsid surface (Fig. 6). Each of the three mutations
reduced the length of the side chain, where it could potentiallyaffect exposure of the determinant and interactions with the
viral surface. Y87F is located in the βC chain two residues
downstream of the BC loop and exposed on the northern edge
of the CAR-binding footprint (He et al., 2001; Muckelbauer
et al., 1995). V136A is located near the carboxy terminus of
the DE loop, close to the five-fold axis of symmetry. This po-
sition does not appear as a surface residue in the CVB3
road map (Muckelbauer et al., 1995), but since residue 135 is
visible, V136A might also be accessible (Michael Rossmann,
personal communication). T276A is positioned three residues
upstream of the viral 2A protease self-cleavage site and closer
to the 2-fold axis of symmetry in an area rich in VP3 residues.
Discussion
Neuromuscular disease caused by the type B coxsackie-
viruses has been recognized since it was first described in
43M.M. Sandager et al. / Virology 372 (2008) 35–47newborn mice infected with nonpolio enteroviruses (Godman
et al., 1952; Melnick et al., 1949). While these early studies
characterized acute cytopathology, our attention has focused on
the sequelae of proximal muscle inflammation and hind limb
weakness that persist following sublethal infection as a model
of chronic PVM. In the current study, we identified the viral
determinants of CVB1T that control development of chronic
PVM. Mice were evaluated at 1 month PI which is on average
two weeks after infectious virus can be cultured but at a time
when viral RNA still persists in skeletal muscle, heart, brain,
and spinal cord (Tam et al., 1994). Four viral determinants, one
in the 5′ UTR at C706 and three in the VP1 capsid gene at Y87,
V136, and T276, control chronic PVM development. Myo-
pathogenicity of the (M-MMM)-A revertant of AMP2.17 fur-
ther substantiates these findings and makes it unlikely that
pathogenesis is tied to any of the six silent mutations previously
identified by sequence comparisons of CVB1T strains (Tam
et al., 2003a).
The location of PVM determinants underscores the impor-
tance of the 5′ UTR and VP1 capsid structure in enterovirus
pathogenesis. In the 5′ UTR, predicted local effects of C706U
include disrupting the basal stem of SLK, located downstream
of the IRES core at nt 432–639 and upstream of the authentic
AUG start codon at nt 743 (Liu et al., 1999). The 40s ribosomal
subunit binds to the pyrimidine-rich Shine–Dalgarno-like se-
quence at nt 566–577 and translocates, most likely by scanning,
through SLK to the AUG initiation codon (Yang et al., 2003).
Structural integrity of this spacer region may be important for
interactions with trans-acting regulatory factors such as La
protein and polypyrimidine-tract binding protein (PTB) (Bhat-
tacharyya and Das, 2005; Hellen et al., 1994). Taking into
consideration the generally-accepted structure of domains I–VI
(Bailey and Tapprich, 2007; Skinner et al., 1989; Zell and Stel-
zner, 1997), C706U is also predicted to cause new long range
pairings in the basal regions of domains III, IV, and V. Changes
in domain III pairing include the highly conserved 5-mer
5′-232CGUUA236-3′ containing the U234C determinant of car-
diovirulence attenuation (Tu et al., 1995). New sites of pairing
in domain Voverlap with the PTB binding site located upstream
of C472U, a determinant of poliovirus attenuation (Guest et al.,
2004; Gutierrez et al., 1997). Phenotypic expression of these
attenuating mutations is often host cell specific, with little to no
effect observed in highly permissive cell lines. Thus, the fact
that amyopathic CVB1T strains are competent for acute repli-
cation in BGMK, HeLa, Neuro-2a, G8, or C2C12 cells, or in
skeletal muscle (unpublished results and (Tam and Messner,
1997; Tam et al., 2003b)), does not preclude the possibility that
C706U modulates the expression of immunostimulatory viral
proteins involved in chronic myositis.
A shared feature of all three VP1 capsid determinants is that
they appear to be exposed on the virion surface. Despite this
and their proximity to known antigenic sites, there is no indi-
cation that B cell recognition and antibody production are
affected by the mutations. The conserved anti-parallel eight-
stranded β-barrel pocket of VP1 provides structural scaffolding
whereas the loops possess greater natural variability. The BC
loop of CVB3 is relatively short (residues 81–85), flanking therim of the CAR-binding canyon (He et al., 2001). In this
position, conversion of a hydrophilic to a hydrophobic residue
at Y87F could have important consequences for CAR binding.
In poliovirus 2-Lansing, the BC loop of VP1 is a determinant of
neurovirulence in mice (Martin et al., 1988; Murray et al.,
1988), where changes in flexibility affect its contact with the
viral receptor (Lentz et al., 1997). Y87F is also located within
two residues of a determinant linked to extended receptor usage
by CVB2 (Polacek et al., 2005). Thus, Y87F is a strong
candidate for altered receptor binding that is linked to patho-
genesis. V136A is located in the DE loop which sits close to the
five-fold axis of symmetry. Although DE loop interactions help
stabilize the viral pentamer, attenuating mutations did not
destabilize the viral capsid at several temperatures or low pH.
Major determinants of attenuation have been mapped within the
DE loop of poliovirus (Ren et al., 1991) and CVB4 (Caggana
et al., 1993). Together, the BC and DE loops form a discon-
tinuous neutralizing antigenic site in poliovirus, indicative of
their close physical association (Wiegers et al., 1989). While
Y87 and V136 do not appear to be part of a neutralizing
antibody epitope in CVB1T, their potential for interaction
may explain their interdependence and activity as a compound
determinant of weakness.
T276A is located at the carboxy terminus of VP1, three
residues upstream of the VP1/2A self-cleavage site (Mulders
et al., 2000). In CVB1T, this sequence is ‘ITTT/G’ with T276A
occupying the P3 position. Presence of a hydrophilic amino acid
at P3 is highly conserved in 2A substrates that contain a T at P2
(Muto et al., 2006). Conversion of a T276 to a hydrophobic
alanine might therefore be expected to alter 2A protease activity
with downstream effects on viral RNA stability, translation, and
negative-strand synthesis (Jurgens et al., 2006) or perhaps dy-
strophin cleavage (Badorff et al., 1999). A second relevant
feature of T276A is its possible involvement in DAF binding,
which is associated with CVB3 virulence (Stadnick et al., 2004).
The DAF-binding footprint on echovirus 7 involves three re-
gions, one of which contains VP1 residues from the carboxy
terminus close to the area where T276A is exposed (He et al.,
2002). Changes in DAF binding would not be unexpected,
considering that the amyopathic parent AMP2 was produced by
thirty sequential passages through BGMK cells (Huang et al.,
2002; Tam and Messner, 1997).
These studies support a mechanism where multiple viral
determinants act in concert to produce full-blown PVM. Our
working model, though speculative, proposes that inflammation
is driven by T cell recognition of immunodominant epitopes
encoded by capsid regions containing Y87 and T276, consistent
with the known involvement of T cells and MHC haplotype in
PVM (Tam and Messner, 1996; Ytterberg et al., 1988). At least
one of these epitopes must also be active in BALB/c (H-2d)
mice. Equivalent antibody responses further imply that these are
not B cell or T helper cell epitopes, focusing attention on cy-
totoxic T cells as possible effectors. Because of its position in
the 5′UTR, C706 may act as a modulator of chronic myositis by
controlling the expression of pathologic VP1 epitopes, which
conforms with the localization of inflammatory cells around
muscle fibers containing persistent viral RNA (Tam et al.,
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when T cell epitopes are strong yet play a larger role when they
are weak, accounting for levels of inflammation that are high for
A-MMM-M but intermediate for M-AAA-M. Notably, muscle
inflammation is linked to but not sufficient for weakness
development, as demonstrated by M-MAM-M. The location of
Y87, V136, and T276 in sites associated with receptor binding
suggests that the inflammatory response could influence
weakness indirectly through upregulation of CAR (Ito et al.,
2000) or other secondary receptors on satellite cells, causing
enhanced cytopathogenicity and a loss of regenerative capacity
that leads to permanent myofiber loss, fatty replacement, and
fibrosis (Tam et al., 1994). These studies reinforce and extend
previous work, linking pathogenesis of weakness and inflam-
mation to four viral genetic determinants that point to immu-
nogenicity and viral tropism as prime candidates for further
mechanistic studies of PVM.
Materials and methods
Viruses and cell culture
MP1.24 (AY186745) and AMP2.17 (AY186747) are
infectious cDNA clones of viruses MP1 and AMP2, respec-
tively, that were derived from the original CVB1T stock SY8
and sequenced as described previously (Tam and Messner,
1997; Tam et al., 2003b). BGMK cells were cultured in DMEM
(Mediatech, Herndon, VA) containing 10% FBS (Atlanta Biolo-
gicals, Norcross, GA)(DMEM-10) at 37 °C in a humidified
atmosphere containing 5% CO2. Virus was prepared by trans-
fecting 1 μg intact plasmid in serum-free DMEM into BGMK
cells using 10 μl Effectene (Qiagen, Valencia, CA) according to
the manufacturer's protocol. The virus was harvested when the
culture attained 100% CPE by freeze–thawing the plate three
times followed by centrifugation at 2500 ×g for 20 min. Virus-
containing supernatants were stored at −80 °C. Titers of viruses
used for injection were determined by adding two-fold dilutions
of virus to 1×104 BGMK cells per well in a 96-well plate. Eight
replicate wells were plated for each virus dilution, and the
TCID50/ml was calculated using the 50% end point (Reed and
Muench, 1938). Titers of virus recovered from muscle were
determined similarly by using ten-fold dilutions of clarified
muscle homogenate.
Mice
Specific pathogen-free ICR (CD-1) mice were purchased at
late-term gestation (Harlan, Indianapolis, IN), and BALB/c
mice (Jax, Bar Harbor, ME) were bred in-house. Dams with
litters were housed in BSL-2 barrier conditions in the Research
Animal Resources facilities at the University of Minnesota. For
CD-1 mice, litters of newborn pups were pooled and redis-
tributed randomly to their original litter size among the dams.
Pups were injected intraperitoneally with 20 TCID50 of virus in
50 μl PBS within 48 h after birth. Each mutant virus was tested
in at least three litters of CD-1 mice. Control litters were
injected with MP1.24, AMP2.17, or PBS in parallel with everybatch of mutant viruses that was evaluated. At the experimental
endpoint, the mice were weighed, exsanguinated, and sacrificed
by cervical dislocation while under ketamine/xylazine anesthe-
sia, in accordance with Public Health Service policy on the
humane care and use of laboratory animals and the research
protocol approved by the Institutional Animal Care and Use
Committee of the University of Minnesota. Moribund mice
were euthanized. With the exception of sham-infected controls,
only mice that had measurable titers of serum antibody to
CVB1T were included to ensure that all mice used in the final
analysis had undergone a productive acute infection. The
overall success rate for infection was similar for all viruses and
averaged 90%.
Site-directed mutagenesis
Single nucleotide site-directed mutagenesis was performed
using mutagenic oligonucleotides and the GeneEditor system
(Promega, Madison, WI) according to the manufacturer's pro-
tocol. The five mutagenic primer sequences, with the targeted nt
shown as myopathic/amyopathic followed by the location of the
corresponding nucleotide (nt) and amino acid changes in
parentheses, were as follows: 5′-CATCACGAATTTTA-C/T-
AACACTAAACTAC-3′ (C706U); 5′-CAAAGAAGGGAT-A/
T-CGCGGAATGGG-3′ (A2712U, Y87F); 5′-GATGCACCC-
G-T/C-CCAAACCCACC-3′ (U2859C, V136A); 5′-CGATT-
GAATATT-A/G-CAACAACTGGAG (A3278G, T276A); 5′-
GAATGACCAG-A/G-AGGTAGGCGTG-3′ (A5510G, K53E).
To minimize the possibility of secondary, non-target mutations,
smaller subgenomic fragments of viral cDNA containing the
region of interest were subcloned, mutagenized, completely
sequenced using Big Dye chemistry followed by analysis on an
ABI3130xl (Applied Biosystems, Foster City, CA) at the
University of Minnesota Biomedical Genomics Center, and
ligated back into the parent clone using compatible restriction
enzyme sites. Restriction site junctions in reformed infectious
clones were verified by sequencing. Sequencing results and
alignments were processed with LaserGene 6.0 (DNASTAR,
Madison, WI).
Clinical weakness and muscle histopathology
Motor dysfunction in the hind limbs, scored as weakness,
was determined as described previously (Tam et al., 1991). In
brief, mice were placed into the bottom half of a large cage and
allowed to move freely while a blinded observer scored effects
on leg position and gait. Each leg was graded on a scale of 0 to 3
as follows: grade 0, no disease; grade 1, leg is slightly splayed
but can still be used to walk and grip a wire screen; grade 2, leg
drags visibly with little or no ability to grip; grade 3, leg exhibits
flexion deformity and cannot be used to walk or grip. Scores
for the right and left leg were combined for a total maximum
weakness grade per mouse of 6. To evaluate muscle histo-
pathology, proximal hind limb muscle was excised as a single
piece containing the hamstring, quadriceps, and femur, fixed in
Zamboni's at 4 °C for a minimum of 2 weeks, decalcified, and
embedded in paraffin. Cross sections were cut at 8 μm and
45M.M. Sandager et al. / Virology 372 (2008) 35–47stained with hematoxylin and eosin. The degree of inflamma-
tion was scored in the right hamstring muscle and graded on a
scale ranging from none (grade 0) to severe (grade 3) as
described previously (Tam et al., 2003b).
Anti-viral antibodies
The level of anti-viral IgG in serum was measured by ELISA
as previously described with MP1.24 as the target (Tam and
Messner, 1996). The ELISA serum standard consisted of serum
pooled from infected mice averaging an A405 of 1.0 at a 1/500
dilution and assigned a value of 5000 U/ml. A standard curve
was included on each 96-well ELISA plate with all samples
assayed in triplicate. Titers of anti-viral antibody in test sera
were calculated using the standard curve and expressed in U/ml.
Sera were considered as positive if they had values N750 U/ml
which is 3 SD above the historical mean for uninfected mice.
Neutralizing antibody titers were determined by performing an
initial 1/32 dilution of mouse serum in DMEM followed by
serial 1/2 dilutions in a 96-well plate, with a final volume of
50 μl diluted serum per well. Each sample was tested at mi-
nimum in triplicate. Fifty microliters of DMEM containing 50
TCID50 of infectious virus was added per well and the plate was
incubated at 37 °C. After 1 h, 100 μl of DMEM-10 containing
1×104 BGMK cells was added per well, the plate was incu-
bated for 4 days, and the wells were scored as positive or
negative for CPE. The final neutralizing antibody titer was
expressed as the log2 of the inverse of the highest dilution of
serum that neutralized infectivity. Horse anti-CVB1 and horse
preimmune serum (ATCC, Manassas, VA) were included as
positive and negative controls, respectively. Uninfected wells
served as an additional negative control, and serum from unin-
fected mice was uniformly negative for neutralizing activity.
Temperature and pH stability
Viruses were diluted to equivalent titers (TCID50/ml) in
DMEM-10 and incubated in a water bath at 37 °C, 39 °C, or
47 °C. Aliquots were withdrawn at the indicated times and
stored frozen at −70 °C until the virus titer was determined as
described above. Stability at pH 4.5 was determined as
described by Vlasak et al. (2005).
RNA secondary structure and capsid homology modeling
Computer models of RNA secondary structure for the CVB1
5′ UTR were created using mfold version 3.2 (Zuker, 2003).
Default folding parameters were used, and multiple sequences
were submitted by the use of the mfold interface developed as
part of this project (software available at http://www.bioinfor-
matics.org/mfoldinterface). The circular Feynman representa-
tion was created with jViz.Rna (Wiese et al., 2005). Homology
models of the wild type MP1.24 capsid and the mutant con-
taining Y87F, V136A, and T276Awere created inModeller (Sali
et al., 1995), available as a module of Insight II (Accelrys, San
Diego, CA), using the atomic structure of the closely-related
CVB3 (1COV.pdb) (Muckelbauer et al., 1995). The homologymodel was visualized with Maestro (Schrodinger, New York,
NY).
Statistics
Statistical analyses were performed using StatView 5.0 (SAS
Institute Inc., Cary, NC). All thirteen mutant viruses were com-
pared to the prototypeMP1.24 and AMP2.17 viruses by ANOVA
with Bonferroni–Dunn post-hoc comparisons to categorize
mutants as myopathic, amyopathic, or intermediate (adjusted
for thirteen mutants compared to two prototypes or twenty-six
comparisons, level of significance α=0.002). Selected individual
mutant viruses were compared using Student's t-test. Additional
details on statistical analyses are described in the results.
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